Skip to content

Efficacy of Buzhong Yiqi Decoction in the Treatment of Ocular Myopathy Myasthenia Gravis (MG) Patients with Spleen and Kidney Deficiency Type: a Randomized Controlled Trial

Efficacy of Buzhong Yiqi Decoction in the Treatment of Ocular Myopathy Myasthenia Gravis (MG) Patients with Spleen and Kidney Deficiency Type: a Randomized Controlled Trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047506
Enrollment
Unknown
Registered
2021-06-20
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular myasthenia gravis

Interventions

Sponsors

Affiliated Jiangmen Traditional Chinese Medicine Hospital of Ji’nan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meets the diagnostic criteria of Western medicine for myasthenia gravis, as well as the diagnosis and syndrome differentiation criteria of Chinese medicine; 2. Patients classified as ocular myasthenia gravis according to the modified Osserman classification; 3. Aged less than 80 years; 4. After understanding the contents of this study in detail, the patients voluntarily accepted observation and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with myasthenia gravis receiving high dose of corticosteroids or other immunosuppressive agents; 2. Patients who have had myasthenia crisis or are experiencing myasthenia in the past 1 month; 3. Severe mental disorders cannot cooperate with clinical investigators; 4. Patients with other neuromuscular diseases or peripheral nerve diseases; 5. Patients complicated with serious primary diseases such as cardiovascular, cerebrovascular, respiratory, digestive or endocrine systems, as well as patients complicated with autoimmune diseases or mental illnesses; 6. Pregnant or lactating women and people with allergies.

Design outcomes

Primary

MeasureTime frame
the absolute and relative Score of MG, ARS-MG;Integral of TCM Syndrome;MG Quality of life 15;

Countries

China

Contacts

Public ContactYu Shangzhen

Affiliated Jiangmen Traditional Chinese Medicine Hospital of Ji’nan University

ysz6521@126.com+86 13500281692

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026